Clinical Trial Search

Primary: Mean Change From Baseline in Total Lesion Count — -26.9 Lesions counted

Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008

Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale

Primary: Number of Correct Responses to Questionnaire Items Immediately Before and After and Educational Lecture — 79; 79; 74; 79 participants

Primary: Number of Inflammatory Lesions (Papules and Pustules) — 6; 3; 10; 0 Lesions

Primary: Mean Change From Baseline to Week 12 in Global Acne Assessment Score (GAAS) — -0.86 score on a scale

Primary: Percent Change From Baseline in Total Lesions at Week 12 — -17.1; -45.6; -13.0; 7.6 Percent change in lesions

Primary: Number of Participants Satisfied and Very Satisfied With Regimen — 42 participants

Primary: Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12 — 69.7; 81.4 Percentage of participants

Primary: The Measured Adherence by the MEMS Cap in Relation to the Patient Reported Adherence Via the Internet Survey. — 74; 32 percentage of days containers were open

Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions

Primary: Inflammatory Lesion Counts — -29.9; -26.7; -24.8; -26.8 lesions

Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947

Primary: Change in Number of Inflammatory Lesions — -30.1 Inflammatory lesions

Primary: Change in Total Acne Lesion Counts — -26.0; -25.2; -29.4; -33.1 Lesions

Primary: Percent Change in Inflammatory Acne Lesion Counts From Baseline to Week 12 — -37.4; -34.7; -30.7; -44.8 Percent change

Primary: Level of IL-1β — 52.5; 361.2 pg/mg

Primary: PGA Score — 0.53 score on a scale

Primary: Total Lesion Count — 76.7; 53.9; 50.0; 43.7 lesions

Primary: Safety (Number of Participants With Treatment Related Adverse Events) — 4; 1; 2; 2 Participants

Primary: Percent Change of Global Face Total Acne Lesion Count From Baseline — -44; -54 Percent change of acne lesion count

Primary: Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment — 16; 14.58; 11.54 Percentage of…

Primary: Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population — 14.1; 15.4; 29.5; 16.4 Percentage…

Primary: Mean Rate of Adherence, as Assessed by Medical Event Monitoring System (MEMS) — 63.1; 56.5; 48.2 percentage of adherence — p=0.3165

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline — 25.4; 14.7 percentage of participants

Primary: Global Face Total Lesion Count - Percent Change - Baseline to Week 12 — -42.64; -47.80 Percent Change in Lesions — p=0.538

Primary: Percent Change in Inflammatory Acne Lesion Counts — -28.6; -44.3; -44.4 Percentage change from baseline — p=0.1919

Primary: Change in Inflammatory Lesions With Daily Use of NAG Compared With Vehicle After 12-weeks of Use. — -27; -44 % change of inflammatory lesions count — p=<0.01

Primary: Mean Percent Change From Baseline in the Papules and Pustules Lesion Count — 68.18; 63.56; 50.72 percentage of lesion change

Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 30.1; 29.8; 15.4; 16.9 Lesions